Compensatory angiogenesis and tumor refractoriness
Open Access
- 1 June 2015
- journal article
- review article
- Published by Springer Science and Business Media LLC in Oncogenesis
- Vol. 4 (6), e153
- https://doi.org/10.1038/oncsis.2015.14
Abstract
Since the establishment of tumor angiogenesis as a therapeutic target, an excitement in developing the anti-angiogenic agents was resulted in tailoring a humanized monoclonal antibody (Bevacizumab) against vascular endothelial growth factor (VEGF): a key factor in recruiting angiogenesis. The past three decades’ research in the area of angiogenesis also invented a series of novel and effective anti-angiogenic agents targeting the VEGF signaling axis. Despite the demonstrable clinical benefits of anti-angiogenic therapy, the preclinical and clinical data of the current therapeutic settings clearly indicate the transient efficacy, restoration of tumor progression and aggressive recurrence of tumor invasion after the withdrawal of anti-angiogenic therapy. Therefore, the impact of this therapeutic regime on improving overall survival of patients has been disappointing in clinic. The recent advances in pathophysiology of tumor angiogenesis and related molecular and cellular underpinnings attributed the conspiracy of compensatory angiogenic pathways in conferring evasive and intrinsic tumor resistance to anti-angiogenic agents. The understandings of how these pathways functionally cross-talk for sustaining tumor angiogenesis during VEGF blockade is essential and perhaps may act as a basic prerequisite for designing novel therapeutic strategies to combat the growing arrogance of tumors toward anti-angiogenic agents. The present review offers a discourse on major compensatory angiogenic pathways operating at cellular and molecular levels and their attributes with resistance to anti-angiogenic agents along with strategic opinions on future setting in targeting tumor angiogenesis.Keywords
This publication has 85 references indexed in Scilit:
- Role of Bone Marrow-Derived Cells in Angiogenesis: Focus on Macrophages and PericytesCancer Microenvironment, 2012
- Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapyTrends in Pharmacological Sciences, 2012
- Molecular control of endothelial cell behaviour during blood vessel morphogenesisNature Reviews Molecular Cell Biology, 2011
- Concise Review: Vascular Stem Cells and Tumor AngiogenesisThe International Journal of Cell Cloning, 2011
- Radiation responses of cancer stem cellsJournal of Cellular Biochemistry, 2009
- Tumor Vasculature Is Regulated by PHD2-Mediated Angiogenesis and Bone Marrow-Derived Cell RecruitmentCancer Cell, 2009
- Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapiesDrug Resistance Updates, 2009
- Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cellsProceedings of the National Academy of Sciences, 2009
- FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?Nature Reviews Cancer, 2008
- Fibroblasts in cancerNature Reviews Cancer, 2006